Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
Since after setting stent ceiling prices on February 14, 2017, the drug price regulator has so far received 40 written complaints against major hospitals.
Roche announced the CE-IVD launch of the cobas® Liat® PCR System with four assays including first 20 minute real-time PCR nucleic acid test to detect Clostridium difficile (C. diff). Countries accepting CE mark are the first to receive access to the cobas® Cdiff test, which detects C. diff in stool specimens from symptomatic patients1 and provides rapid and definitive results in under 20 minutes. Timely and accurate diagnosis of this infection is important because it can quickly become life threatening, especially to high-risk patients such as the elderly, immuno-compromised and those undergoing antibiotic treatment.
Cipla Ltd, a global pharmaceutical company, announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Abacavir and Lamivudine Tablets USP, 600 mg/300 mg, from the United States Food and Drug Administration (USFDA).
ProQR Therapeutics N.V. announced the grant of two key patents protecting QR-010 in the US and EU. These patents provide the Company exclusive rights for QR-010 for the treatment of cystic fibrosis (CF) until at least July 2033.
U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). This is the first drug approved by the FDA for PPMS. Ocrevus is an intravenous infusion given by a health care professional.
Divi's Laboratories Limited got Import Alert 66-40 issued by US-FDA on products manufactured at the company’s Unit-II at Yisakhapatnam, Andhra Pradesh
The choice of President Donald Trump to head the US Food and Drug Administration is among the strongest advocates of lowering drug costs by quickly approving cheap generics, an initiative aimed directly at profit centers Of large companies.
The Department of Biotechnology (DBT), India and the Netherlands Organization for Scientific Research (NWO) / the Netherlands Organization for Health Research and Development (ZonMw) will soon jointly initiate research on Health care. This program provides funding opportunities for joint research cooperation between Dutch and Indian research groups.
Three strategic issues to be addressed under this program. First, how can technology support people's health and well-being in order to help them function and participate in society outside of organized care? The point is to focus on health rather than on health care. By focusing on prevention, health and wellness, you reduce the need for professional health care. Second, how can technology make it easier for people to get closer to home? In many cases, it is more cost effective and better for patients to provide care outside of health care facilities. Chronic care should not be managed in hospitals. Rehabilitation should take place closer to home or even at home. Third, how can technology enable more effective and personalized care? Technology allows us to do more with less. The technology can allow for early and individualized diagnosis and prognosis, less invasive treatment and change work processes all together.
The purpose of this joint research program is to stimulate a sustainable Indian-Dutch research collaboration by funding joint research projects in the field of medical devices with the explicit objective of contributing to more sustainable health care in India or Netherlands. It also aims to develop innovative technologies for a sustainable health system.
In addition to providing solutions to the above questions, another objective is to stimulate the Dutch and Indian research fields of medical devices on the minimally invasive techniques.
Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Meropenem Injection 500 mg/vial and 1 g/vial. Aurobindo’s Meropenem injection is a generic equivalent of AstraZeneca Pharmaceuticals’ Merrem® Injection. The product will be launched immediately.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
